5-alpha reductase inhibitors use in prostatic disease and beyond.

Publication Year: 2023

DOI:
10.21037/tau-22-690

PMCID:
PMC10080355

PMID:
37032761

Journal Information

Full Title: Transl Androl Urol

Abbreviation: Transl Androl Urol

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Urology & Nephrology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://tau.amegroups.com/article/view/10.21037/tau-22-690/coif). EC serves as an unpaid editorial board member of Translational Andrology and Urology from August 2022 to July 2024. MLP reports that he has received the Australiasian Fulbright Commission Scholarship through the Kinghorn Foundation. The other authors have no conflicts of interest to declare."

Evidence found in paper:

"Funding: None."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025